Can a bioreactor predict ovarian cancer chemo success?
NCT ID NCT07461207
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aims to see if a special device called a U-Cup bioreactor can predict how well standard chemotherapy will work in women with high-grade ovarian cancer. Researchers will take tumor samples from 120 patients before treatment and test them in the lab. The goal is to find out which patients are likely to respond and which might need different therapies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a lab test that helps doctors choose the right chemotherapy for each ovarian cancer patient.
- What could go wrong
- This is an early observational study, not a treatment trial. The tool may not accurately predict responses in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
Mar 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Women with high-grade serous ovarian cancer, not previously treated with chemotherapy, who are candidates for surgery at the UOC Ginecologia Oncologica De Iaco - IRCCS AOUBO
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age\>= 25 years * Obtained informed consent * Histological and/or surgical diagnosis of high-grade serous ovarian carcinoma * Patients who have not undergone surgical treatment * Availability of primary/metastatic tumor tissue for sampling Exclusion Criteria: * Patients with comorbidities * Patients with other malignancies
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for High-grade serous ovarian carcinoma (hgsoc) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Bologna, 40138, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.